榮昌生物-B(09995.HK)上半年營收達4.191億元 同比增長20%
格隆匯8月21日丨榮昌生物-B(09995.HK)公佈中期業績,截至2023年6月30日止六個月,集團收益約為人民幣4.191億元,毛利約為人民幣3.164億元。期間虧損增加約人民幣2.142億元或約43.8%至約人民幣7.034億元。研發開支增加約人民幣9080萬元或約20.2%至約人民幣5.405億元。截至2023年6月30日止,集團銀行結餘及現金為約人民幣11.197億元。
集團截至2023年6月30日止六個月的產品銷售及研發服務收益約為人民幣4.191億元,較去年同期的人民幣3.488億元增長20%,主要得益於公司自身免疫類商業化產品泰它西普(RC18,商品名:泰愛®)及抗腫瘤類商業化產品維迪西妥單抗(RC48,商品名:愛地希®)的銷售放量導致銷售收入同比增長強勁。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.